The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AGIOS PHARMACEUTICALS INC | COM | 00847X104 | 14,172,950 | 484,711 | SH | SOLE | 484,711 | 0 | 0 | |||
| ALIMERA SCIENCES INC | COM NEW | 016259202 | 65,657,101 | 16,835,154 | SH | SOLE | 16,835,154 | 0 | 0 | |||
| ANIKA THERAPEUTICS INC | COM | 035255108 | 36,474,222 | 1,435,993 | SH | SOLE | 1,435,993 | 0 | 0 | |||
| BIOCRYST PHARMACEUTICALS INC | COM | 09058V103 | 3,853,190 | 758,502 | SH | SOLE | 758,502 | 0 | 0 | |||
| ENANTA PHARMACEUTICALS INC | COM | 29251M106 | 14,981,902 | 858,070 | SH | SOLE | 858,070 | 0 | 0 | |||
| EVOLUS INC | COM | 30052C107 | 26,444,334 | 1,888,881 | SH | SOLE | 1,888,881 | 0 | 0 | |||
| EXELIXIS INC | COM | 30161Q104 | 26,120,323 | 1,100,730 | SH | SOLE | 1,100,730 | 0 | 0 | |||
| I MAB | SPONSORED ADS | 44975P103 | 1,407,161 | 756,538 | SH | SOLE | 756,538 | 0 | 0 | |||
| LIQUIDIA CORPORATION | COM NEW | 53635D202 | 152,823,939 | 10,360,945 | SH | SOLE | 10,360,945 | 0 | 0 | |||
| OUTLOOK THERAPEUTICS INC | COM | 69012T305 | 5,970,000 | 500,000 | SH | SOLE | 500,000 | 0 | 0 | |||
| VERONA PHARMA PLC | SPONSORED ADS | 925050106 | 20,859,832 | 1,296,447 | SH | SOLE | 1,296,447 | 0 | 0 | |||
| Y-MABS THERAPEUTICS INC | COM | 984241109 | 9,549,108 | 587,276 | SH | SOLE | 587,276 | 0 | 0 | |||